Location: Norway
Total raised: $75.5M
Funding Rounds 1
| Date | Series | Amount | Investors |
| 10.07.2025 | Series A | $75.5M | M Ventures |
Mentions in press and media 4
| Date | Title | Description |
| 14.07.2025 | Actithera Secures $75.5 Million to Propel Precision Radioligand Therapies | Actithera, a cutting-edge biotech firm, recently secured $75.5 million in oversubscribed Series A funding. This significant capital injection powers their precision radioligand therapy (RLT) initiatives. Funds will advance their lead FAP as... |
| 10.07.2025 | Actithera: $75.5 Million Series A Raised For Transforming Precision Radioligand Therapy | Actithera, a biotech company specializing in radiopharmaceuticals, has secured $75.5 million in an oversubscribed Series A financing round. This funding will help advance their lead FAP (Fibroblast Activation Protein) asset into clinical de... |
| 09.07.2025 | Actithera Raises $75.5M in Series A Funding | Actithera, an Oslo, Norway-, and Cambridge, MA-based radiopharmaceutical biotech company developing radioligand therapies (RLTs), raised $75.5M in Series A funding. The round was led by M Ventures and new investors Hadean Ventures, Sofinnov... |
| - | Actithera | “Actithera’s targeted radioligand therapy platform enables truly personalized cancer treatment that requires fewer, more tolerable cycles of therapy.” |